Targeting tumours with genetically enhanced T lymphocytes

Nat Rev Cancer. 2003 Jan;3(1):35-45. doi: 10.1038/nrc971.


The genetic modification of T lymphocytes is an important approach to investigating normal T-cell biology and to increasing antitumour immunity. A number of genetic strategies aim to increase the recognition of tumour antigens, enhance antitumour activities and prevent T-cell malfunction. T cells can also be engineered to increase safety, as well as to express markers that can be tracked by non-invasive imaging technologies. Genetically modified T cells are therefore proving to be of great value for basic immunology and experimental immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antigen Presentation
  • Antigens, Neoplasm / immunology
  • Humans
  • Immunotherapy*
  • Killer Cells, Lymphokine-Activated / immunology
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Neoplasms / genetics
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Receptors, Antigen, T-Cell / immunology
  • T-Lymphocytes / immunology*
  • T-Lymphocytes, Regulatory / immunology


  • Adjuvants, Immunologic
  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Receptors, Antigen, T-Cell